Sai Parenterals Secures ₹104.50 Cr Exclusive Anti-TB Supply Contract from Philippines
Sai Parenterals has bagged a ₹104.50 crore long-term purchase order from Philippines-based PILL CORP for the exclusive supply of anti-tuberculosis products. This ten-year contract marks a significant international expansion and provides substantial long-term revenue visibility for the newly listed pharmaceutical firm.
Senores Pharmaceuticals Reports 108% PAT Growth in FY26; Eyes Strong FY27 Guidance
Senores Pharmaceuticals delivered a significant financial beat for FY26, characterized by a 62% increase in revenue and a 108% rise in net profit. The company's strategic focus on the US regulated market and a doubling of its approved ANDA portfolio has positioned it for aggressive expansion in the coming fiscal year.
Lupin Reports Record ₹27,958 Cr Revenue in FY26; US Business Surges 40 Percent
Lupin achieved record-breaking financial performance in FY26, driven by a 40% surge in its US business and steady growth in India's chronic segment. The company handsomely beat its margin guidance, reporting an EBITDA margin of 29.7% against an original expectation of 27-28%.
Emcure Pharmaceuticals Crosses $1 Billion Revenue Milestone as FY26 PAT Surges 41%
Emcure Pharmaceuticals achieved a significant milestone in FY26 by surpassing $1 billion in annual revenue, driven by a 16.6% growth in total income. The company reported a robust 41% increase in adjusted PAT, underpinned by strong expansion in international markets and a resilient domestic portfolio.
Shelter Pharma Launches FOLIMAN Folic Acid Tablets in International Markets
Shelter Pharma Ltd has officially introduced its new healthcare product, FOLIMAN Folic Acid Tablets, on May 11, 2026. The Vitamin B-9 supplement is initially being rolled out in international markets as part of the company's strategic expansion into the global nutraceutical segment.
Lupin Limited Reports 32% Q4 Revenue Growth as FY26 EBITDA Surges 68%
Lupin Limited delivered a record-breaking performance in FY26, characterized by significant surges in US generic sales and a robust prescription business in India. While the company exceeded margin guidance for the year, management has signaled a more conservative stance for FY27 to account for upcoming competitive pressures in key product categories.
Kabra Drugs Announces AI-Defense Tech Hub and Pharma Expansion in South India
Kabra Drugs Limited is diversifying its operations by establishing an AI-integrated defense research facility in Chennai and expanding its pharmaceutical manufacturing footprint across South India. The dual-sector strategy aims to leverage high-growth therapeutic markets and national security technology opportunities to drive long-term value creation.
Emcure Pharmaceuticals Achieves ₹9,204 Cr Revenue Milestone; Targets Margin Growth in FY27
Emcure Pharmaceuticals surpassed the $1 billion revenue milestone in FY26, driven by a 22.2% surge in international markets. While domestic restructuring led to a temporary Q4 slowdown in the Zuventus portfolio, management has guided for margin expansion and steady growth for FY27.
Auro Laboratories Secures EDQM Approval for Metformin Hydrochloride Facility at Tarapur
Auro Laboratories has received a formal Attestation of Inspection from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its MIDC Tarapur facility. This regulatory milestone confirms the site's compliance with European Union Good Manufacturing Practice (GMP) standards for the production of Metformin Hydrochloride.